Chemotherapy-related secondary acute myeloid leukemia in patients diagnosed with osteosarcoma

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 7, 2004, Pages 454-456

  Escudero, M Carmen ^a   Lassaletta, Alvaro ^a,b   Sevilla, Julian ^a   Fernandez Plaza, Sandra ^a   Pérez, Antonio ^a   Diaz, Miguel A ^a   Madero, Luis ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

Alkylating agents; Osteosarcoma; Platinum; Secondary leukemia; Topoisomerase II inhibitors

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DACTINOMYCIN; DOXORUBICIN; GYRASE INHIBITOR; IFOSFAMIDE; METHOTREXATE; PLATINUM COMPLEX; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ANEMIA; ARTICLE; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL FEATURE; FEVER; HEADACHE; HUMAN; LEUKOPENIA; MALE; OSTEOSARCOMA; PETECHIA; PRIORITY JOURNAL; PURPURA; SECOND CANCER;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; NEOPLASMS, SECOND PRIMARY; OSTEOSARCOMA;

EID: 3543137244     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200407000-00012     Document Type: Article

References (14)

1. Kawai A, Sugihara S, Naito N, et al. Development of acute myeloid leukemia after chemotherapy for osteosarcoma. Clin Orthop. 2001;391:239-246.
2. Aung L, Gorlick RG, Shi W, et al. Second malignant neoplasms in long-term survivors of osteosarcoma. Cancer. 2002;95:1728-1734.
3. Panizo C, Patiño A, Calasanz MJ, et al. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: implications of germline TP53 mutations. Med Pediatr Oncol. 1998;30:165-169.
4. Viehmann S, Teigler-Schlegel A, Brunch J, et al. Monitoring minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia. 2003;17:1130-1136.
5. Pui CH, Hancock ML, Raimondi SC, et al. Myeloid neoplasia in children treated for solid tumors. Lancet. 1990;336:417-421.
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
7. Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs. 2003;63:1565-1577.
8. Schneider DT, Hilgenfeld E, Schwabe D, et al. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. J Clin Oncol. 1999;17:3226-3233.
9. Philpott NJ, Elebute MO, Powles R, et al. Platinum agents and secondary myeloid leukaemia: two cases treated only with platinum-based drugs. Br J Haematol. 1996;93:884-887.
10. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340:351-357.
11. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17:569-577.
12. Fenaux P, Jouet JP, Baurers F. Translocation t(9;11)(p21;q23) with acute myelomonocytic leukemia after chemotherapy for osteosarcoma: good response to antileukemic drugs. J Clin Oncol. 1987;5:1304-1305.
13. Pedersen-Bjergaad J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplastic after high-dose chemotherapy and autologous stem transplantation. Blood. 2000;95:3273-3279.
14. Pegram A, Kennedy LD. Prevention and treatment of veno-occlusive disease. Ann Pharmacother. 2001;35:935-942.